Immunity to melanoma antigens: from self-tolerance to immunotherapy
/in International Publications, Malignant Melanoma /von 2006-01-01 / Adv. Immunol. 2006;90:243-95Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells
/in International Publications, Malignant Melanoma /von 2005-12-06 / Cancer Immunol. Immunother. 2006 Oct;55(10):1209-18Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2005-12-01 / Clin. Exp. Immunol. 2005 Dec;142(3):555-68Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells
/in International Publications, Malignant Melanoma /von 2005-11-29 / Cancer Immunol. Immunother. 2006 Oct;55(10):1238-46Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy
/in International Publications, Malignant Melanoma /von 2005-11-26 / Cancer Immunol. Immunother. 2006 Aug;55(8):1011-6Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma
/in International Publications, Malignant Melanoma /von 2005-11-01 / Anticancer Res. 2005 Nov-Dec;25(6A):3741-6Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity
/in International Publications, Malignant Melanoma /von 2005-11-01 / Clin. Cancer Res. 2005 Nov;11(21):7692-9Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2005-09-27 / Cancer Immunol Immunother 2006 Jul;55(7):819-29Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
/in International Publications, Malignant Melanoma /von 2005-09-01 / J. Immunother. 2005 Sep-Oct;28(5):505-16
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de